Enteral Nutrition Market Owing to Rising Prevalence of Chronic Diseases

Purvaja Jadhao

posted on 9 months ago — updated on 1 second ago

75
views

Enteral Nutrition Market Owing to Rising Prevalence of Chronic Diseases

The enteral nutrition market is estimated to be valued at US$ 3.1 Bn in 2023 and is expected to exhibit a CAGR of 5.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Enteral nutrition refers to the delivery of nutrients directly into the gastrointestinal tract of patients. It is prescribed for patients facing difficulty in consuming nutrition orally or due to impaired functioning of the gastrointestinal system. Products associated with enteral nutrition include enteral feeding tubes, enteral feeding formulas, and enteral syringes. These products find widespread adoption in pediatric and adult patients suffering from chronic diseases, cancer, neurological disorders, and other conditions affecting digestion.

Market Dynamics:
The enteral nutrition market is primarily driven by the rising prevalence of chronic diseases such as diabetes, gastrointestinal disorders, cancer, and neurological disorders globally. As per WHO, cancer is the second leading cause of death globally, with approximately 10 million deaths in 2020. Likewise, approx. 422 million people suffered from diabetes in 2014 according to International Diabetes Federation. Enteral nutrition products play a crucial role in the clinical management of chronically ill patients facing malnutrition or problems with oral intake. Another factor aiding the market growth includes the growing geriatric population who are more prone to chronic diseases and nutritional deficiencies. However, risks associated with enteral feeding tubes like infections, blockages, and nutrient malabsorption restrict the market to a certain extent.

SWOT Analysis
Strength: Enteral nutrition provides effective nutritional support for patients unable to meet nutritional needs through diet. It allows delivery of balanced nutrition and helps in weight management. Many big players allow customization of products as per specific nutritional needs.
Weakness: Dependence on tube or tube placement surgery makes the process invasive. It requires trained professionals for product administration and entails risks of complications. Storage and handling of products requires strict protocols.
Opportunity: Rising prevalence of chronic diseases and conditions driving nutritional deficiency open growth avenues. Increasing awareness about clinical nutrition benefits expands the customer base. Development of less invasive and user-friendly products bolsters the market potential.
Threats: High costs associated with enteral nutrition limits widespread adoption. Reimbursement issues in certain regions poses commercialization challenges. Substitute options like parenteral nutrition act as alternatives.

Key Takeaways
The global enteral nutrition market is expected to witness high growth, exhibiting a CAGR of 5.8% over the forecast period, due to increasing prevalence of chronic disorders.

Market size: The global enteral nutrition market size was valued at US$ 3.1 Bn in 2023 and is anticipated to reach over US$ 4.5 Bn by 2030.

Regional analysis: North America dominated the global enteral nutrition market in 2023 due to rising geriatric population and chronic disease burden in the region. Asia Pacific exhibits highest growth potential owing to increasing health awareness, healthcare investments and economic growth in many Asian countries.

Key players: Key players operating in the enteral nutrition market are Abbott, Nestlé S.A., Danone S.A., Fresenius Kabi AG, Mead Johnson & Company, LLC, Braun Melsungen AG, Otsuka Pharmaceutical Co., Ltd, Meiji Holdings Co., Ltd., Bahrain Pharma, Bionova Lifesciences, Global Health Products Inc., Victus Inc., Curtis Health Caps SP.